menstrual related migraine
Conditions
Interventions
Sham-electroacupuncture group:Sham-electroacupuncture treatment
Sponsors
Longhua Hospital Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Participants will be eligible for inclusion if they meet the following inclusion criteria: 1) meet the diagnostic criteria for MRM without aura according to the International Classification of Headache Disorders (ICHD-3); 2) female aged 18-50 years; 3) the courses of MRM without aura last more than 12 months; 4) the frequency of migraine attack is 2-8 time on average and days less than 15 days in one month within 3 months before enrollment; 5) with regular menstrual cycle; 6) consent to participate in this study and sign the written informed consent.
Exclusion criteria
Exclusion criteria: Participants will be excluded if they meet any of the following criteria: 1) the presence of other types of primary or secondary headache; 2) a combination of severe cardiovascular and cerebrovascular neurologic hematological and acute infectious diseases; 3) active or previous history of peptic ulcer disease gastrointestinal bleeding or perforation; 4) those who use preventive migraine medicine in the last 3 months; 5) with planned pregnancy during the treatment period oral contraceptive distribution or during the period of pregnancy or lactation; 6) those who have received acupuncture treatment within one year; 7) with cardiac pacemakers; 8) with metal allergy or serious fear of needle.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the change in the number of migraine days and attacks during weeks 9 to 12 compared to the baseline.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Average dosage and frequency of emergency drugs from baseline to 24 weeks.;Treatment response rate, which is the proportion of patients with a reduction of = 50%, 75%, or 100% per four weeks migraine days in weeks 1-4, weeks 5-8, weeks 9-12, weeks 13-16, weeks 17-20 and weeks 21-24 compared with the baseline;Changes in the PHQ-9 after the end of treatment at week 12 compared with baseline;Changes in the mean duration per four weeks of migraine attacks in weeks 1-4, weeks 5-8, weeks 9-12, weeks 13-16, weeks 17-20, and weeks 21-24 compared with the baseline.;Changes in the number of days and attacks of migraine per four weeks of menstrual period and non-menstrual period in weeks 1-4, weeks 5-8, weeks 9-12, weeks 13-16, weeks 17-20 and weeks 21-24 compared with the baseline.;Changes in the number of days and attacks of migraine-associated symptoms (nausea, vomiting, photophobia, and phonophobia) in weeks 1-4, weeks 5-8, weeks 9-12, weeks 13-16, weeks 17-20 and weeks 21-24 compared with the baseline.;Changes in the number of migraine days and attacks in weeks 1-4, weeks 5-8, weeks 13-16, weeks 17-20, and weeks 21-24 compared with the baseline.;Changes in the MIDAS after the end of treatment at week 12 compared with baseline;Changes in the ISI after the end of treatment at week 12 compared with baseline;Changes in the number of days and attacks of migraine per four weeks of menstrual period period in weeks 1-4, weeks 5-8, weeks 9-12, weeks 13-16, weeks 17-20 and weeks 21-24 compared with the baseline.;Changes in the mean VAS scores per four weeks of migraine attacks in weeks 1-4, weeks 5-8, weeks 9-12, weeks 13-16, weeks 17-20, and weeks 21-24 compared with the baseline.;Changes in the GAD-7 after the end of treatment at week 12 compared with baseline; | — |
Contacts
Public Contactping yin
Longhua Hospital Shanghai University of Traditional Chinese Medicine
Outcome results
None listed